SRPT
Sarepta Therapeutics Inc.
$18.80
+$1.37(+7.83%)
25
Overall
--
Value
25
Tech
--
Quality
Market Cap
$1.77B
Volume
7.56M
52W Range
$10.42 - $138.81
Target Price
$23.88
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $1.3M | $5.4M | $154.6M | $602.1M | $380.8M | $455.9M | $612.4M | $843.8M | $1.1B | $1.8B | ||
| Total Revenue | $1.3M | $5.4M | $154.6M | $301.0M | $380.8M | $540.1M | $701.9M | $933.0M | $1.2B | $1.9B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $221.4M | $-101.0K | $-35.8M | $-34.2M | $-66.6M | $-63.4M | $97.0M | $140.0M | $150.3M | $319.1M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $1.3M | $5.5M | $190.4M | $335.2M | $447.4M | $476.7M | $604.8M | $793.0M | $1.2B | $1.6B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $221.4M | $272.1M | $290.4M | $610.5M | $1.0B | $1.0B | $1.1B | $1.3B | $1.4B | $1.4B | ||
| Research & Development | $146.4M | $188.3M | $166.7M | $401.8M | $734.1M | $722.3M | $771.2M | $877.1M | $877.4M | $804.5M | ||
| Research Expense | $146.4M | $188.3M | $166.7M | $401.8M | $734.1M | $722.3M | $771.2M | $877.1M | $877.4M | $804.5M | ||
| Selling, General & Administrative | $75.0M | $83.7M | $122.7M | $207.8M | $284.8M | $317.9M | $282.7M | $451.4M | $481.9M | $557.9M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | -- | -- | $14.6M | $28.6M | $32.0M | ||
| General & Administrative Expenses | $75.0M | $83.7M | $122.7M | $207.8M | $284.8M | $317.9M | $282.7M | $451.4M | $481.9M | $557.9M | ||
| Salaries & Wages | $-32.1M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $4.7M | $29.0K | $1.1M | $900.0K | $800.0K | $700.0K | $700.0K | $714.0K | $1.6M | $2.4M | ||
| Depreciation & Amortization | $4.7M | $29.0K | $1.1M | $900.0K | $800.0K | $700.0K | $700.0K | $714.0K | $1.6M | $2.4M | ||
| Amortization | -- | $29.0K | $1.1M | $900.0K | $800.0K | $700.0K | $700.0K | $714.0K | $1.6M | $2.4M | ||
| Other Operating Expenses | $-613.0K | $-801.0K | $-735.0K | $-2.2M | $-4.3M | $-6.7M | $-5.5M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-220.2M | $-266.7M | $-171.6M | $-343.6M | $-705.6M | $-564.2M | $-459.7M | $-536.2M | $-267.8M | $218.1M | ||
| EBITDA | $-214.1M | $-259.7M | $-35.6M | $-324.3M | $-667.2M | $-466.2M | $-317.4M | $-648.1M | $-475.7M | $316.9M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | $1.9M | $5.8M | $33.7M | $30.7M | $59.9M | $63.5M | $53.2M | -- | $18.4M | ||
| Intinc | $154.0K | $507.0K | $1.8M | $6.8M | $7.2M | $3.0M | $354.0K | $16.5M | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $154.0K | $-1.4M | $-4.0M | $-26.9M | $-23.4M | $-57.0M | $-63.2M | $25.5M | $58.3M | $49.0M | ||
| Other Income/Expense | $-154.0K | $535.0K | $-123.0M | $19.0M | $8.3M | $-95.3M | $-130.2M | $-128.2M | $153.8M | $-156.7M | ||
| Other Special Charges | $154.0K | $-535.0K | $123.0M | $-19.0M | $-8.3M | $95.3M | $130.2M | $-64.5M | $-153.8M | $156.7M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | $4.6M | $3.0M | $-2.2M | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | -- | $-4.6M | $-3.0M | $2.2M | -- | -- | -- | $6.9M | $-617.0K | $2.8M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | $4.5M | $2.6M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-220.0M | $-265.4M | $-42.8M | $-328.9M | $-683.2M | $-493.1M | $-355.4M | $-690.0M | $-520.1M | $279.2M | ||
| Pre-Tax Income | $-220.0M | $-267.3M | $-48.6M | $-362.6M | $-713.9M | $-553.1M | $-418.9M | $-690.0M | $-520.1M | $260.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | $2.1M | $-692.0K | $1.2M | $1.1M | $-168.0K | $13.5M | $15.9M | $25.5M | ||
| NET INCOME | ||||||||||||
| Net Income | $-220.0M | $-267.3M | $-50.7M | $-361.9M | $-715.1M | $-554.1M | $-418.8M | $-703.5M | $-536.0M | $235.2M | ||
| Net Income (Continuing Operations) | $-220.0M | $-267.3M | $-50.7M | $-361.9M | $-715.1M | $-554.1M | $-418.8M | $-703.5M | $-536.0M | $235.2M | ||
| Net Income (Discontinued Operations) | $-220.0M | $-267.3M | $-50.7M | $-361.9M | $-715.1M | $-554.1M | $-418.8M | $-703.5M | $-536.0M | $235.2M | ||
| Net Income (Common Stockholders) | $-220.0M | $-267.1M | $20.9M | $7.5M | $-581.9M | $-554.1M | $-418.8M | $-703.5M | $-536.0M | $235.2M | ||
| Normalized Income | $-143.0M | $-169.2M | $-28.6M | $-363.3M | $-564.0M | $-436.3M | -- | -- | -- | -- | ||
| TOTALS | ||||||||||||
| Total Expenses | $442.9M | $271.9M | $254.7M | $576.3M | $953.2M | $977.5M | $947.5M | $1.5B | $1.4B | $1.7B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $42.3M | $48.7M | $58.8M | $66.3M | $73.6M | $78.0M | $81.3M | $87.6M | $92.4M | $95.1M | ||
| Average Shares Outstanding (Diluted) | $42.3M | $48.7M | $58.8M | -- | $73.6M | $78.0M | $81.3M | $87.6M | $92.4M | $107.9M | ||
| Shares Outstanding | $45.7M | $54.8M | $65.0M | $71.3M | $77.8M | $79.4M | $87.1M | $88.0M | $93.9M | $97.0M | ||
| Basic EPS | -- | $-5.49 | $-0.86 | $-5.46 | $-9.71 | $-7.11 | $-5.15 | $-8.03 | $-5.8 | $2.47 | ||
| Basic EPS (Continuing Operations) | -- | $-5.49 | $-0.86 | $-5.46 | $-9.71 | $-7.11 | $-5.15 | $-8.03 | $-5.8 | $2.47 | ||
| Diluted EPS | $-5.2 | $-5.49 | $-0.86 | $-5.46 | $-9.71 | $-7.11 | $-5.15 | $-8.03 | $-5.8 | $2.34 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-8.03 | $-5.8 | $2.34 | ||
| OTHER METRICS | ||||||||||||
| Minority Interests | $190.3M | $336.7M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $75.0M | $83.7M | $122.7M | $207.8M | $284.8M | $317.9M | $282.7M | $451.4M | $481.9M | $557.9M | ||
| Rent And Landing Fees | $5.2M | $5.6M | $4.4M | $7.9M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | $4.6M | $3.0M | $-2.2M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SRPT | $18.80 | +7.8% | 7.56M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Sarepta Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW